Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Piątkiewicz, Paweł." wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-5 z 5
    Tytuł:
    WYKORZYSTANIE MONITORINGU MEDIÓW W BADANIACH EKSTREMIZMU POLITYCZNEGO
    THE APPLICATION OF MEDIA MONITORING IN POLITICAL EXTREMISM RESEARCH
    Autorzy:
    GAWROŃSKI, SŁAWOMIR
    Piątkiewicz, Paweł
    Powiązania:
    https://bibliotekanauki.pl/articles/513104.pdf
    Data publikacji:
    2018
    Wydawca:
    Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
    Tematy:
    media monitoring,
    political extremism,
    media studies
    Opis:
    The article presents the possibilities provided by applying media studies (media monitoring) in political studies. The author showcases theoretical connections between the impact of mass media and the phenomenon of political extremism. It also presents a case study – a research project carried out in Liechtenstein regarding the monitoring of political extremism. The article contains recommendations for the possible implementa-tion of the project in other countries. The research methods appliedwere limited to the analysis of literature in the field of political extremism and the methods of media studies. The desk research method was also used for the case study.
    Źródło:
    Polityka i Społeczeństwo; 2018, 16, 3; 7-18 (12)
    1732-9639
    Pojawia się w:
    Polityka i Społeczeństwo
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Autoimmunity markers in subjects with diabetes
    Autorzy:
    Litwińczuk-Hajduk, Joanna
    Bernat-Karpińska, Małgorzata
    Kowrach, Marek
    Cielecka-Kuszyk, Joanna
    Piątkiewicz, Paweł
    Powiązania:
    https://bibliotekanauki.pl/articles/972601.pdf
    Data publikacji:
    2016
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    diabetes
    anty-GAD
    ANA
    ASMA
    APCA
    Opis:
    Introduction. Diabetes is a growing social and epidemiological problem. Accordingly, the incidence of complications associated with diabetes can cause a persistent high percentage of diseases of the cardiovascular system, kidney and nervous systems, and impaired vision. Objective. The aim of the study was to evaluate the incidence of immunological markers in patients with type 1 diabetes and those with type 2 diabetes: the anti-GAD, ANA, AMA, ASMA, APCA and LKM, compared to healthy people. Another objective of the study was to evaluate the correlation between their presence and the degree of metabolic control in both groups. Materials and methods. The study comprised 100 subjects aged 25–75 years with a body mass index (BMI) between 20–30 kg / m2, hospitalized in the Department of Internal Diseases, Diabetology and Endocrinology, at the Medical University of Warsaw, with previously diagnosed diabetes who were assigned to one of 2 groups (50 subjects with type 1 diabetes and 50 subjects with type 2 diabetes). The control group consisted of 21 healthy individuals without the diagnosis of diabetes and a prediabetic state. All the study participants had the examined antibodies determined along with the panel of biochemical tests and neurological examination for diabetic neuropathy and fundus examination. Results. Anti-GAD antibodies were present in both groups of patients. Their presence was found in 30% of people with type 1 diabetes and in 16% of people with diabetes type 2. The presence of ANA antibodies was found in 24% of people with type 1 diabetes and 22% of people with type 2 diabetes. There was no correlation between the presence of ANA antibodies ANA and duration of diabetes. In the group of patients with type 1 diabetes, there was a correlation between the presence of ANA and the incidence of diabetic polyneuropathy. ASMA and APCA antibodies occurred with equal frequency in both studied groups (4% vs. 10%). There were no antibodies of AMA or anti-LKM in any of the patients. Conclusions. Marking of ANA antibodies in patients with type 1 diabetes may be a marker used to isolate a group of patients at risk of developing diabetic neuropathy. The presence of anti-GAD in type 2 diabetes may be a LADA marker which specifically marks the group of patients with type 2 diabetes, in whom there is a faster metabolic death of beta cells. The current classification of diabetes is vague, and in the near future it should be modified based on specific patient characteristics, phenotypic appearance, as well as the results of additional tests. Determination of antibodies AMA, ASMA, APCA and anti-LKM does not seem to be significant in the diagnosis of diabetes and its chronic complications.
    Źródło:
    Journal of Pre-Clinical and Clinical Research; 2016, 10, 1; 28-33
    1898-2395
    Pojawia się w:
    Journal of Pre-Clinical and Clinical Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Levels of interleukin-2 in patients with colon cancer and diabetes type 2
    Autorzy:
    Bosek, Irina
    Sulich, Agnieszka
    Rabijewski, Michał
    Kaleta, Beata
    Kniotek, Monika
    Miłek, Tomasz
    Piątkiewicz, Paweł
    Powiązania:
    https://bibliotekanauki.pl/articles/972606.pdf
    Data publikacji:
    2016
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    diabetes type 2
    colon cancer
    interleukin-2
    Opis:
    Introduction and objective: The risk of development colon cancer (CC) is increased significantly among patients with the type 2 diabetes (T2DM). A mechanism responsible for the higher prevalence of CC among diabetic patients may be associated with the immunity system. The aim of this study is to point out the differences in the immunity state in terms of interleukin 2 level among patients with T2DM suffering from CC, and patients without these diseases Material and Methods: 79 patients were included the tests, divided into 4 groups: Group 1–23 people with T2DM, Group 2–23 people with large intestine CC, Group 3–10 people with large CC and T2DM, and Group 4–23 people without T2DM or CC. Each patient had a colonoscopy and those with cancer were confirmed in a histopathological examination. Laboratory measurements included fasting glucose, insulin, C-peptide. The concentration of interleukin-2 in serum was determined with the immunoenzymatic (ELISA) method. Results: The results obtained showed that in patients with T2DM and CC the concentration of interleukin-2 was statistically higher than in the other groups.(4.21±1.61 pg/ml vs. Group 1 -1.64±0.44 pg/ml, Group 2–1.54±0.21 pg/ml, and Group 4–1.70±0.36 pg/ml; p<0.05). Insulin levels, C-peptide and HOMA-IR did not differ significantly between groups, but a tendency was observed to higher values of HOMA-IR and insulin levels in the groups with T2DM alone and T2DM with concomitant CC. Conclusions: The data show differences in the immunity state of patients with T2DM and CC, compared with people without those two diseases. Elevated level of interleukin 2 found in this group, after confirmation in other studies with more patients, could be used as a marker of an increased risk of CC in people with T2DM
    Źródło:
    Journal of Pre-Clinical and Clinical Research; 2016, 10, 1; 1-5
    1898-2395
    Pojawia się w:
    Journal of Pre-Clinical and Clinical Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-5 z 5

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies